Belviq Tablet® Post Marketing Surveillance Protocol

Launched by ILDONG PHARMACEUTICAL CO LTD · Nov 12, 2018

Keywords

ClinConnect Summary

Lorcaserin(Belviq) is a selective 5-hydroxytryptamine receptor agonist, witch is used long term for weight loss in those who are obese. Lorcaserin was approved in 2015 the Republic of Korea for weigh loss in those who are obese. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of lorcaserin for weigh loss in real-world practice.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects who use the drug as an adjuvant therapy of diet therapy and kinesitherapy for weight control are selected.
• • 1. Obese patients whose body mass index (BMI) is ≧30 kg/m2.
• • 2. Overweight patients whose body mass index(BMI) is ≧27 kg/m2 and who have other risk factors(e.g. hypertension, dyslipidemia, type II diabetes mellitus)
• Exclusion Criteria:
• • 1. Patients with a hypersensitivity reaction to the drug or the ingredient of the drug
• • 2. Female patients of childbearing potential and pregnant or lactating women
• • 3. Patients taking another weight control drug
• • 4. Patients with the medical history of drug abuse